In 405 Cuban patients with advanced lung cancer, the EGF vaccine CIMAvax-EGF after chemotherapy gave a median survival of 10.8 months against 8.9 with supportive care; the difference was significant only by a weighted test and among patients who had at least four doses.
Published as "A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients". CIMAvax-EGF is human recombinant epidermal growth factor joined to a carrier protein with the adjuvant Montanide ISA51, intended to make the body produce antibodies that block EGF from reaching its receptor. Four to six weeks after first-line chemotherapy, 405 patients with stage IIIB or IV non-small cell lung cancer were randomised to the vaccine or to best supportive care.
The main evidence for Cuba's lung cancer vaccine: well tolerated, with a survival gain that depends on how the analysis is done and that was clearest in patients who completed the induction doses.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB, Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), CIMAB, EGFR.
Shares CIMAvax-EGF, National Coordinating Centre of Clinical Trials, Cuba (CENCEC).
Shares National Coordinating Centre of Clinical Trials, Cuba (CENCEC), Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Shares CIMAB, Non-small-cell lung cancer.
Shares Instituto Nacional de Oncología y Radiobiología (INOR), Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/